跳至主要内容
临床试验/NCT00132665
NCT00132665已完成3 期

Randomized Controlled Trial to Evaluate Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatine in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer (JCOG0301, NCSLC-Elderly-CBDCA-RT Phase III)

Japan Clinical Oncology Group74 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2003年7月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
200
试验地点
74
主要终点
Overall survival

研究概览

简要总结

The purpose of this study is to evaluate whether radiotherapy with carboplatin will result in longer survival than radiotherapy alone in elderly patients with unresectable stage III NSCLC.

详细描述

The purpose of this study is to evaluate whether radiotherapy with carboplatin will result in longer survival than radiotherapy alone in elderly patients with unresectable stage III NSCLC.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
71 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically and/or cytologically proven NSCLC
  • Unresectable disease
  • Stage IIIA except T3N1M0 and IIIB which does not have disease extended to any contralateral hilar nodes, atelectasis of the entire lung or malignant pleural effusions
  • A required radiation field of less than one half of one lung
  • Measurable disease
  • No previous chemotherapy or radiotherapy
  • Age >= 71
  • Unable to receive cisplatin-based combination chemotherapy
  • ECOG performance status (PS) of 0-2
  • Adequate bone marrow, lung, hepatic, and renal function
  • Written informed consent

排除标准

  • Active infection, diarrhea, ileus, uncontrolled diabetes, myocardial infarction within three months, or severe other comorbidity
  • Synchronous cancer or metachronous (within 5 years) malignancy
  • Interstitial pneumonia or active lung fibrosis on chest X-ray
  • Severe chronic obstructive pulmonary disease, chronic bronchitis, or bronchial asthma
  • Pleural or pericardial effusion
  • A history of severe hypersensitivity
  • Mental disorder
  • Judging of inappropriate condition for this study by physician

结局指标

主要结局

Overall survival

时间窗: During the study conduct

次要结局

  • Response rate(During the study conduct)
  • Adverse events(During the study conduct)
  • Progression-free survival(During the study conduct)
  • Pattern of progression/relapse(During the study conduct)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (74)

Loading locations...

相似试验